Candidate: The applicant is an associate professor of Neurology at the university of Maryland and a staff neurologist at the Baltimore VA Medical Center. Current academic activities include clinical and basic research in multiple sclerosis (MS). Currently, there are two ongoing research projects in the applicant's laboratory: The first is a VA funded Merit Review Award through March, 2002 to examine mechanisms of virus persistence in human neurons, and the second is to examine the therapeutic mechanisms of 2 newly approved drugs for MS, IFNbeta and copolymer-1. During the past 6-years four postdoctoral fellows conducted research related to MS in the applicant's laboratory. Environment: The Maryland Center for MS is internationally recognized for clinical and basic research in MS. Clinical research at this center contributed to the FDA approval of 2 of the 3 currently marketed drugs for MS namely Betaseron and copolymer-1. More than 800 annual patient visits occur, and the center participates in several multisite clinical trials. The center is staffed by 5 full time MS specialists, 3 nurses, and 2 support staff. Research: The proposed research will focus on understanding the therapeutic mechanisms of Betaseron and copolymer-1 in MS. Supplies and partial technical support for this research is currently provided by Berlex and TEVA, the manufacturers of Betaseron and copolymer-1 respectively.
Our specific aims i nclude: 1. Examination of the modulatory effect of IFNbeta treatment on IL-12 in MS. IL-12 is a pro-inflammatory cytokine implicated in the pathogenesis of MS. Preliminary data indicate that IFNbeta has a cell-specific regulatory effect on IL-12 in peripheral blood mononuclear cells (PBMNC). We will examine the mechanism of this regulatory effect both in vitro and ex-vivo using PBMNC from MS patients pre- and post-treatment with IFNbeta. The findings will also be correlated with MRI disease activity. 2. Mechanisms of Copolymer-I therapy in MS. We will examine the immunologic effects of copolymer-1 in PBMNC obtained ex-vivo from MS patients treated with this drug. This includes induction of copolymer-1 specific regulatory cells, whether these cells cross react with myelin antigens and induce cytokine deviation, or whether copolymer-1 produces T-cell anergy. The proposed research could help identify components of the immunologic network in MS that are associated with response to treatment, and therefore help in the design of more effective future therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
7K24NS002082-06
Application #
6834188
Study Section
NST-2 Subcommittee (NST)
Program Officer
Utz, Ursula
Project Start
1999-05-02
Project End
2006-04-30
Budget Start
2003-08-01
Budget End
2006-04-30
Support Year
6
Fiscal Year
2003
Total Cost
$108,800
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Neurology
Type
Schools of Medicine
DUNS #
617022384
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Wei, Changran; Wang, Ying; Li, Xiangqi (2018) The role of Hippo signal pathway in breast cancer metastasis. Onco Targets Ther 11:2185-2193
Graber, Jerome J; Ford, David; Zhan, Min et al. (2007) Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol 185:168-74
Graber, J; Zhan, M; Ford, D et al. (2005) Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J Neuroimmunol 161:169-76
Dhib-Jalbut, Suhayl; Mouradian, M Maral (2004) Delivery of transgenically modified adult bone marrow cells to the rodent central nervous system. Expert Opin Biol Ther 4:669-75
Dhib-Jalbut, Suhayl (2003) Glatiramer acetate (Copaxone) therapy for multiple sclerosis. Pharmacol Ther 98:245-55
Chen, Man; Valenzuela, Reuben Mari; Dhib-Jalbut, Suhayl (2003) Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 215:37-44
Dhib-Jalbut, Suhayl; Chen, Man; Said, Areen et al. (2003) Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol 140:163-71
Dhib-Jalbut, S; Chen, M; Henschel, K et al. (2002) Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler 8:485-91
Dhib-Jalbut, Suhayl (2002) Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58:S3-9
Chen, M; Conway, K; Johnson, K P et al. (2002) Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci 201:71-7

Showing the most recent 10 out of 13 publications